NewTrimEra Sema-X
The benchmark GLP receptor agonist for sustained metabolic control.
A long-acting glucagon-like peptide analogue designed for once-weekly subcutaneous administration. Studied extensively for glycemic regulation and chronic weight management.
How it works
Selectively binds the GLP receptor, augmenting glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and modulating central appetite signaling in the hypothalamus.
What the evidence shows
STEP-1 trial: mean −14.9% body weight at 68 weeks vs. −2.4% placebo.
Reduced HbA1c by ~1.5–1.8% in T2DM cohorts.
Demonstrated cardiovascular risk reduction in the SUSTAIN-6 trial.
97% structural homology to native human GLP-1.
Cited data reflects published clinical trials of the underlying molecule. Individual response varies. Statements have not been evaluated by the FDA.